Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Chaudhry, Amina A ^a   Botsko, Michael ^b   Weiss, Linda ^c   Egan, James E ^c   Mitty, Jennifer ^d   Estrada, Barbara ^e   Lucas, Gregory M ^a   Woodson, Tanita ^a   Flanigan, Timothy P ^f   Fiellin, David A ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Center for HIV Educational Studies and Training   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Impact Consultants Inc   (United States)

^f BROWN UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

buprenorphine; heroin dependence; HIV; methadone; opioid related disorders

Indexed keywords

AMPHETAMINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; METHADONE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; CANNABIS ADDICTION; CONDOM; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; FEMALE; HIGH RISK BEHAVIOR; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OPIATE ADDICTION; PRIORITY JOURNAL; SUBSTANCE ABUSE; UNITED STATES; UNSAFE SEX; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE SHARING; ODDS RATIO; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RISK-TAKING; UNSAFE SEX;

EID: 79951792799     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318209d3b9     Document Type: Article

References (75)

1. Substance Abuse and Mental Health Services Administration. (2010). Results From the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings). Rockville, MD. Available at: http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9 ResultsP.pdf. Accessed September 21, 2010.
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339, Rockville, MD, 2008. Available at: http://dawninfo.samhsa.gov/ files/ED2006/DAWN2K6ED. pdf. Accessed January 12, 2011.
3. Oppenheimer E, Tobutt C, Taylor C, et al. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction. 1994;89:1299-1308. (Pubitemid 24310621)
4. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. a clinical trial with methadone hydrochloride. JAMA. 1965;193:646-650.
5. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7:249-256. (Pubitemid 11078403)
6. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485-488. (Pubitemid 9256690)
7. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958. (Pubitemid 37064768)
8. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475-486. (Pubitemid 28188067)
9. Kakko J, Dybrandt Svanborg K, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662-668. (Pubitemid 36246548)
10. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Rockville, MD Treatment Episode Data Set (TEDS). Data received through 10.6.08. Available at: http://www.oas.samhsa.gov/ teds2k7highlights/ TEDSHighl2k7Tbl4.htm. Accessed January 12, 2011.
11. Umbricht-Schneiter A, Ginn DH, Pabst KM, et al. Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health. 1994;84:207-210. (Pubitemid 24138452)
12. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58:861-868. (Pubitemid 32979305)
13. Rubin AS, Littenberg B, Ross R, et al. Effects on processes and costs of care associated with the addition of an internist to an inpatient psychiatry team. Psychiatr Serv. 2005;56:463-467. (Pubitemid 40471590)
14. Weisner C, Mertens J, Parthasarathy S, et al. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001; 286:1715-1723. (Pubitemid 33010257)
15. Weaver MR, Conover CJ, Proescholdbell RJ, et al. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J Ment Health Policy Econ. 2009;12:33-46.
16. Centers for Disease Control and Prevention. HIV Prevalence Estimates- United States. 2006. MMWR 2008;57:1073-1076. Available at: http:// www.cdc.gov/mmwr/PDF/wk/mm5739.pdf. Accessed January 12, 2011.
17. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care Psychological and Socio-Medical Aspects of AIDS/HIV. 2004;16:199-211. (Pubitemid 38183583)
18. Berg KM, Demas PA, Howard AA, et al. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19:1111-1117. (Pubitemid 39552581)
19. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185-194.
20. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381. (Pubitemid 34626108)
21. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquired Immune Defic Syndr. 2006;43:411-417. (Pubitemid 44737097)
22. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose- response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29:1190-1197. (Pubitemid 41060434)
23. Cunningham WE, Sohler NL, Tobias C, et al. Health services utilization for people with HIV infection: comparison of a population targeted for outreach with the US population in care. Med Care. 2006;44:1038-1047. (Pubitemid 44674036)
24. Metsch LR, Pereyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abuse. 2001;13:155-167. (Pubitemid 38209968)
25. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health. 2003;80:667-675. (Pubitemid 38146230)
26. Conigliaro J, Gordon AJ, McGinnis KA, et al. How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? J Acquir Immune Defic Syndr. 2003;33:521-525. (Pubitemid 36886082)
27. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774. (Pubitemid 34274467)
28. Gowing L, Farrell M, Bornemann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;2:CD004145.
29. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-1056. (Pubitemid 23239778)
30. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994;8:223-231. (Pubitemid 24094119)
31. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35:87-92. (Pubitemid 351734596)
32. Wall TL, Sorensen JL, Batki SL, et al. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995;37:261-269.
33. McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict. 2002;11:271-278. (Pubitemid 35332504)
34. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628-1635.
35. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006; 43:S184-190. (Pubitemid 44901886)
36. Cheever LW, Kresina TF, Cajina A, et al. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S3-S6.
37. Weiss L, Egan JE, Botsko M et al. A multi-site evaluation of integrated buprenorphine/naloxone and HIV treatment: overview of the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S7-S13.
38. Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/ naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S68-S75.
39. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26-33. (Pubitemid 10187569)
40. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595-605. (Pubitemid 13019024)
41. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1171-1178. (Pubitemid 28527173)
42. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385-401.
43. Sullivan LE, Botsko M, Cunningham C, et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S54-S61.
44. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:83-88. (Pubitemid 32183566)
45. Samet JH, Horton NJ, Meli S, et al. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004;28:572-577. (Pubitemid 38506891)
46. Cunningham CO, Sohler NL, Berg KM, et al. Type of substance use and access to HIV-related health care. AIDS Patient Care STDs. 2006;20: 399-407. (Pubitemid 43993094)
47. Metsch LR, Virginia McCoy H, McCoy CB, et al. Use of health care services by women who use crack cocaine. Women Health. 2000;30:35-51.
48. Moyer A, Finney JW, Swearingen CE, et al. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction. 2002;97: 279-292. (Pubitemid 34250722)
49. Aharonovich E, Hatzenbuehler ML, Johnston B, et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care. 2006;18:561-568. (Pubitemid 44050512)
50. Centers for Disease Control and Prevention. HIV-Associated Behaviors Among Injecting-Drug Users-23 Cities, United States, May 2005- February 2006. MMWR 2009, 58: 329-332. Available at: http:// www.cdc.gov/mmwr/pdf/wk/mm5813. pdf. Accessed January 12, 2011.
51. Note Erratum published at http://www.cdc.gov/mmwr/PDF/wk/ mm5850.pdf.
52. Leigh BC, Schafer J, Temple MT. Alcohol use and contraception in first sexual experiences. J Behav Med. 1995;18:81-95.
53. Kalichman SC, Cain D, Zweben A, et al. Sensation seeking, alcohol use and sexual risk behaviors among men receiving services at a clinic for sexually transmitted infections. J Stud Alcohol. 2003;64:564-569. (Pubitemid 36903922)
54. Liu A, Kilmarx P, Jenkins RA, et al. Sexual initiation, substance use, and sexual behavior and knowledge among vocational students in northern Thailand. Int Fam Plan Perspect. 2006;32:126-135. (Pubitemid 47028613)
55. Thompson JC, Kao TC, Thomas RJ. The relationship between alcohol use and risk-taking sexual behaviors in a large behavioral study. Prev Med. 2005;41:247-252. (Pubitemid 40755086)
56. Cook RL, McGinnis KA, Kraemer KL, et al. Intoxication before intercourse and risky sexual behavior in male veterans with and without human immunodeficiency virus infection. Med Care. 2006; 44:S31-36. (Pubitemid 44284255)
57. Leigh BC, Temple MT, Trocki KF. The relationship of alcohol use to sexual activity in a US national sample. Soc Sci Med. 1994;39:1527-1535.
58. Leigh BC. Alcohol and condom use: a meta-analysis of event-level studies. Sex Transm Dis. 2002;29:476-482. (Pubitemid 34851784)
59. Justus AN, Finn PR, Steinmetz JE. The influence of traits of disinhibition on the association between alcohol use and risky sexual behavior. Alcohol Clin Exp Res. 2000;24:1028-1035. (Pubitemid 30604322)
60. Messiah A, Bloch J, Blin P. Alcohol or drug use and compliance with safer sex guidelines for STD/HIV infection. Results from the French National Survey on Sexual Behavior (ACSF) among heterosexuals. Analyse des Comportements Sexuels en France. Sex Transm Dis. 1998;25:119-124. (Pubitemid 28117348)
61. Morrison DM, Gillmore MR, Hoppe MJ, et al. Adolescent drinking and sex: findings from a daily diary study. Perspect Sex Reprod Health. 2003; 35:162-168. (Pubitemid 36980606)
62. Corbin WR, Fromme K. Alcohol use and serial monogamy as risks for sexually transmitted diseases in young adults. Health Psychol. 2002;21:229-236. (Pubitemid 34438950)
63. Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis. 2004;38:890-894. (Pubitemid 38387241)
64. Lyketsos CG, Hanson A, Fishman M, et al. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med. 1994;24:103-113. (Pubitemid 24253677)
65. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580. (Pubitemid 36577260)
66. Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:159-166. (Pubitemid 46292218)
67. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health. 2004;94:1133-1140. (Pubitemid 38857313)
68. McCarty D, Argeriou M, Huebner RB, et al. Alcoholism, drug abuse, and the homeless. Am Psychol. 1991;46:1139-1148.
69. Koegel P, Burnam MA. Alcoholism among homeless adults in the inner city of Los Angeles. Arch Gen Psychiatry. 1988;45:1011-1018. (Pubitemid 18261764)
70. Fischer PJ, Breakey WR. The epidemiology of alcohol, drug, and mental disorders among homeless persons. Am Psychol. 1991;46:1115-1128.
71. Spinner GF, Leaf PJ. Homelessness and drug abuse in New Haven. Hosp Community Psychiatry. 1992;43:166-168.
72. Kidder DP, Wolitski RJ, Campsmith ML, et al. Health status, health care use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS. Am J Public Health. 2007;97: 2238-2245. (Pubitemid 351194704)
73. Susser E, Miller M, Valencia E, et al. Injection drug use and risk of HIV transmission among homeless men with mental illness. Am J Psychiatry. 1996;153:794-798. (Pubitemid 26170541)
74. Metsch LR, McCoy CB, McCoy HV, et al. HIV-related risk behaviors and seropositivity among homeless drug-abusing women in Miami, Florida. J Psychoactive Drugs. 1995;27:435-446. (Pubitemid 26020126)
75. Elwood WN, Williams ML, Bell DC, et al. Powerlessness and HIV prevention among people who trade sex for drugs ('strawberries'). AIDS Care. 1997;9:273-284. (Pubitemid 27292311)